Grant Aids Sami Labs to Complete Two Novel Research Projects
PISCATAWAY, N.J., May 27, 2008 — Sabinsa Corporation today announced that Sami Labs, its research and manufacturing arm in Bangalore, India, received funding from the Government of India's Department of Scientific and Industrial Research (DSIR) to perform pilot trials on two novel research projects.
Sami Labs was awarded $185,000 under the Department's Technology Development and Demonstration Programme, designed to help promote India's research, development and technology advancements. The grant will be used in part to develop and test a plant-derived cosmetic active, with expected market availability in late 2008. In addition, the grant will assist Sami Labs in developing a novel method to manufacture Resveratrol utilizing Sami Labs' patented synthetic Demethylation strategy.
"Sami Labs considers this sanction by DSIR as a recognition of its sustained efforts to pioneer and explore novel areas of research to improve human health and wellness," said Dr. Muhammed Majeed, founder and CEO of Sabinsa.
Additionally, India's National Accreditation Board for Testing & Calibration Laboratories successfully audited Sami Labs research & development and quality control labs. The accreditation certificate provides further validation of Sami Labs' equipment, analytical methods, data systems and regulation compliance.
Sabinsa Corporation is a manufacturer and supplier of herbal extracts, cosmeceuticals, minerals and specialty fine chemicals. Celebrating its 20th year servicing the natural products industry, Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and wellbeing. Over the past several years, the company has brought to market more than 50 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 scientists working full time conducting ongoing research both in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. Sabinsa has six state-of-the-art manufacturing facilities in India dedicated to the production of herbal extracts, phytochemicals, biotech ingredients and supercritical extracts. In the U.S., the company operates a 42,000-square-foot facility in Payson, Utah, which provides cutting-edge capabilities for the development of capsules, tablets, bulk custom pre-mixes, drum-to-hopper blends, stick packs and powdered drinks. All of Sabinsa's facilities use effluent water treatment systems and are environmentally conscious and friendly. All products are intended for human consumption and certified Kosher. For more information visit www.sabinsa.com.
# # #